Share

EORTC presentations at ESMO World Congress on Gastrointestinal Cancer

The EORTC will present one oral abstract and one poster abstract at the 17th ESMO World Congress on Gastrointestinal Cancer which will be held 01 – 04 July 2015 in Barcelona.

Poster P-310

carmela-caballeroC. Caballero, S. Evrard, G. Poston
EORTC 1409-GITCG CLIMB: An EORTC-ESSO Prospective Colorectal Liver Metastasis Database with an Integrated Quality Assurance Program
Friday, 3 July from 10:25 to 10:55 and 16:30 to 17:00
Citation: Ann Oncol (2015) 26 (suppl 4): iv91

Oral Abstract O-018

Theo-RuersT. Ruers, C.J.A. Punt, F. van Coevorden, J.-P. Pierie, I. Borel Rinkes, J. Ledermann, G. Poston, W. Bechstein, M.-A. Lentz, M. Mauer, E. Van Cutsem, M. Lutz, B. Nordlinger
Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC)
July 2015
Citation: Ann Oncol (2015) 26 (suppl 4): iv114-iv115

Follow on Twitter  #WorldGI, #EORTC

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023